论文部分内容阅读
健康志愿受试者１０名，随机分为两组，间隔一周交叉口服头孢羟氨苄颗粒剂和胶囊７５０ｍｇ。用高效液相色谱法测定人血清中头孢羟氨苄浓度，进行相对生物利用度研究。结果表明：颗粒剂与胶囊的体内过程均符合具有滞后时间的一级吸收一级消除的一房室模型，Ｔｐｅａｋ分别为６０．２５±８．５１ｍｉｎ和８２．８０±１５．７７ｍｉｎ，Ｃｍａｘ分别为２４．３６±３．０９ｍｓ／Ｌ和２２．２７±２．４６ｍｇ／Ｌ，ＡＵＣ分别为４２０７．３０±６１９．４１ｍｇ·Ｌ（－１）·ｍｉｎ和４５１８．２７±４０１．９６ｍｇ·Ｌ（－１）·ｍｉｎ；经配对Ｔ检验，两种剂型的Ｔ（１／２）（Ｋａ）、Ｔｐｅａｋ、Ｔｌａｇ有明显差异，其它参数间无显著性差异（Ｐ＞０．０５）。颗粒剂的相对生物利用度为９３．１％。
Healthy volunteers 10 were randomly divided into two groups, one week interval cross oral cefadroxil granules and capsules 750mg. The concentration of cefadroxil in human serum was determined by high performance liquid chromatography and the relative bioavailability was studied. The results showed that the in vivo process of granules and capsules were in accordance with the one-compartment model of first-order absorption elimination with lag time, Tpeak was 60.25 ± 8.51min and 82.80 ± 15.77min, Cmax were 24.36 ± 3.09ms / L and 22.27 ± 2.46mg / L, AUC was 4207.30 ± 619.41mg · L -1 · min and 4518.27 ± 401.96mg · L, respectively 1) · min. There was a significant difference between the two formulations of T (1/2) (Ka), Tpeak and Tlag by paired T-test. There was no significant difference between the other two parameters (P> 0.05). The relative bioavailability of granules was 93.1%.